The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Liver Failure Therapeutics-Global Market Insights and Sales Trends 2025
Synopsis
The global Liver Failure Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Liver Failure Therapeutics in various end use industries. The expanding demands from the Clinic, Hospital and Others,, are propelling Liver Failure Therapeutics market. Ornithine Phenylacetate, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the MTL-CEBPA segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Liver Failure Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Liver Failure Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Liver Failure Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Liver Failure Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Liver Failure Therapeutics covered in this report include Alfact Innovation, BioLineRx Ltd, Cell2B Advanced Therapeutics SA, Conatus Pharmaceuticals Inc, Immune Pharmaceuticals Inc, Mina Therapeutics Ltd, Mylan NV, Ocera Therapeutics Inc and PledPharma AB, etc.
The global Liver Failure Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Alfact Innovation
BioLineRx Ltd
Cell2B Advanced Therapeutics SA
Conatus Pharmaceuticals Inc
Immune Pharmaceuticals Inc
Mina Therapeutics Ltd
Mylan NV
Ocera Therapeutics Inc
PledPharma AB
Promethera Biosciences SA
Silence Therapeutics Plc
Unicyte AG
Ventria Bioscience
Vital Therapies Inc
Global Liver Failure Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Liver Failure Therapeutics market, Segment by Type:
Ornithine Phenylacetate
MTL-CEBPA
F-573
BL-1220
PP-100
Others
Global Liver Failure Therapeutics market, by Application
Clinic
Hospital
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Liver Failure Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Liver Failure Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Liver Failure Therapeutics in various end use industries. The expanding demands from the Clinic, Hospital and Others,, are propelling Liver Failure Therapeutics market. Ornithine Phenylacetate, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the MTL-CEBPA segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Liver Failure Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Liver Failure Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Liver Failure Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Liver Failure Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Liver Failure Therapeutics covered in this report include Alfact Innovation, BioLineRx Ltd, Cell2B Advanced Therapeutics SA, Conatus Pharmaceuticals Inc, Immune Pharmaceuticals Inc, Mina Therapeutics Ltd, Mylan NV, Ocera Therapeutics Inc and PledPharma AB, etc.
The global Liver Failure Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Alfact Innovation
BioLineRx Ltd
Cell2B Advanced Therapeutics SA
Conatus Pharmaceuticals Inc
Immune Pharmaceuticals Inc
Mina Therapeutics Ltd
Mylan NV
Ocera Therapeutics Inc
PledPharma AB
Promethera Biosciences SA
Silence Therapeutics Plc
Unicyte AG
Ventria Bioscience
Vital Therapies Inc
Global Liver Failure Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Liver Failure Therapeutics market, Segment by Type:
Ornithine Phenylacetate
MTL-CEBPA
F-573
BL-1220
PP-100
Others
Global Liver Failure Therapeutics market, by Application
Clinic
Hospital
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Liver Failure Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Liver Failure Therapeutics
1.1 Liver Failure Therapeutics Market Overview
1.1.1 Liver Failure Therapeutics Product Scope
1.1.2 Liver Failure Therapeutics Market Status and Outlook
1.2 Global Liver Failure Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Liver Failure Therapeutics Market Size by Region (2018-2029)
1.4 Global Liver Failure Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Liver Failure Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Liver Failure Therapeutics Market Size (2018-2029)
1.6.1 North America Liver Failure Therapeutics Market Size (2018-2029)
1.6.2 Europe Liver Failure Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Liver Failure Therapeutics Market Size (2018-2029)
1.6.4 Latin America Liver Failure Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Liver Failure Therapeutics Market Size (2018-2029)
2 Liver Failure Therapeutics Market by Type
2.1 Introduction
2.1.1 Ornithine Phenylacetate
2.1.2 MTL-CEBPA
2.1.3 F-573
2.1.4 BL-1220
2.1.5 PP-100
2.1.6 Others
2.2 Global Liver Failure Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Liver Failure Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Liver Failure Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Liver Failure Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Liver Failure Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Liver Failure Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Liver Failure Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Liver Failure Therapeutics Revenue Breakdown by Type (2018-2029)
3 Liver Failure Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Clinic
3.1.2 Hospital
3.1.3 Others
3.2 Global Liver Failure Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Liver Failure Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Liver Failure Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Liver Failure Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Liver Failure Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Liver Failure Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Liver Failure Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Liver Failure Therapeutics Revenue Breakdown by Application (2018-2029)
4 Liver Failure Therapeutics Competition Analysis by Players
4.1 Global Liver Failure Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Liver Failure Therapeutics as of 2022)
4.3 Date of Key Players Enter into Liver Failure Therapeutics Market
4.4 Global Top Players Liver Failure Therapeutics Headquarters and Area Served
4.5 Key Players Liver Failure Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Liver Failure Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Alfact Innovation
5.1.1 Alfact Innovation Profile
5.1.2 Alfact Innovation Main Business
5.1.3 Alfact Innovation Liver Failure Therapeutics Products, Services and Solutions
5.1.4 Alfact Innovation Liver Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Alfact Innovation Recent Developments
5.2 BioLineRx Ltd
5.2.1 BioLineRx Ltd Profile
5.2.2 BioLineRx Ltd Main Business
5.2.3 BioLineRx Ltd Liver Failure Therapeutics Products, Services and Solutions
5.2.4 BioLineRx Ltd Liver Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 BioLineRx Ltd Recent Developments
5.3 Cell2B Advanced Therapeutics SA
5.3.1 Cell2B Advanced Therapeutics SA Profile
5.3.2 Cell2B Advanced Therapeutics SA Main Business
5.3.3 Cell2B Advanced Therapeutics SA Liver Failure Therapeutics Products, Services and Solutions
5.3.4 Cell2B Advanced Therapeutics SA Liver Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Conatus Pharmaceuticals Inc Recent Developments
5.4 Conatus Pharmaceuticals Inc
5.4.1 Conatus Pharmaceuticals Inc Profile
5.4.2 Conatus Pharmaceuticals Inc Main Business
5.4.3 Conatus Pharmaceuticals Inc Liver Failure Therapeutics Products, Services and Solutions
5.4.4 Conatus Pharmaceuticals Inc Liver Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Conatus Pharmaceuticals Inc Recent Developments
5.5 Immune Pharmaceuticals Inc
5.5.1 Immune Pharmaceuticals Inc Profile
5.5.2 Immune Pharmaceuticals Inc Main Business
5.5.3 Immune Pharmaceuticals Inc Liver Failure Therapeutics Products, Services and Solutions
5.5.4 Immune Pharmaceuticals Inc Liver Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Immune Pharmaceuticals Inc Recent Developments
5.6 Mina Therapeutics Ltd
5.6.1 Mina Therapeutics Ltd Profile
5.6.2 Mina Therapeutics Ltd Main Business
5.6.3 Mina Therapeutics Ltd Liver Failure Therapeutics Products, Services and Solutions
5.6.4 Mina Therapeutics Ltd Liver Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Mina Therapeutics Ltd Recent Developments
5.7 Mylan NV
5.7.1 Mylan NV Profile
5.7.2 Mylan NV Main Business
5.7.3 Mylan NV Liver Failure Therapeutics Products, Services and Solutions
5.7.4 Mylan NV Liver Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Mylan NV Recent Developments
5.8 Ocera Therapeutics Inc
5.8.1 Ocera Therapeutics Inc Profile
5.8.2 Ocera Therapeutics Inc Main Business
5.8.3 Ocera Therapeutics Inc Liver Failure Therapeutics Products, Services and Solutions
5.8.4 Ocera Therapeutics Inc Liver Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Ocera Therapeutics Inc Recent Developments
5.9 PledPharma AB
5.9.1 PledPharma AB Profile
5.9.2 PledPharma AB Main Business
5.9.3 PledPharma AB Liver Failure Therapeutics Products, Services and Solutions
5.9.4 PledPharma AB Liver Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 PledPharma AB Recent Developments
5.10 Promethera Biosciences SA
5.10.1 Promethera Biosciences SA Profile
5.10.2 Promethera Biosciences SA Main Business
5.10.3 Promethera Biosciences SA Liver Failure Therapeutics Products, Services and Solutions
5.10.4 Promethera Biosciences SA Liver Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Promethera Biosciences SA Recent Developments
5.11 Silence Therapeutics Plc
5.11.1 Silence Therapeutics Plc Profile
5.11.2 Silence Therapeutics Plc Main Business
5.11.3 Silence Therapeutics Plc Liver Failure Therapeutics Products, Services and Solutions
5.11.4 Silence Therapeutics Plc Liver Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 Silence Therapeutics Plc Recent Developments
5.12 Unicyte AG
5.12.1 Unicyte AG Profile
5.12.2 Unicyte AG Main Business
5.12.3 Unicyte AG Liver Failure Therapeutics Products, Services and Solutions
5.12.4 Unicyte AG Liver Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.12.5 Unicyte AG Recent Developments
5.13 Ventria Bioscience
5.13.1 Ventria Bioscience Profile
5.13.2 Ventria Bioscience Main Business
5.13.3 Ventria Bioscience Liver Failure Therapeutics Products, Services and Solutions
5.13.4 Ventria Bioscience Liver Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.13.5 Ventria Bioscience Recent Developments
5.14 Vital Therapies Inc
5.14.1 Vital Therapies Inc Profile
5.14.2 Vital Therapies Inc Main Business
5.14.3 Vital Therapies Inc Liver Failure Therapeutics Products, Services and Solutions
5.14.4 Vital Therapies Inc Liver Failure Therapeutics Revenue (US$ Million) & (2018-2023)
5.14.5 Vital Therapies Inc Recent Developments
6 North America
6.1 North America Liver Failure Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Liver Failure Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Liver Failure Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Liver Failure Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Liver Failure Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Liver Failure Therapeutics Market Dynamics
11.1 Liver Failure Therapeutics Industry Trends
11.2 Liver Failure Therapeutics Market Drivers
11.3 Liver Failure Therapeutics Market Challenges
11.4 Liver Failure Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
